Slide 1: Investor Conference Call Preliminary FY 2024 Results | 2025 Outlook
Investor Conference Call Preliminary FY 2024 Results | 2025 Outlook Joachim Kreuzburg, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | January 28, 2025
Slide 2: Fiscal 2024 closed with very good fourth quarter and positive trend; FY guidance fully achieved
Sartorius Group Fiscal 2024 closed with very good fourth quarter and positive trend; FY guidance fully achieved ▪ Preliminary results for the Group and both divisions in line with July financial guide ▪ Market recovery gaining momentum: Industry gradually returning to its robust structural growth tr
Slide 3: Agenda
Agenda Sartorius Group FY2024 results | FY 2025 outlook Sartorius Stedim Biotech Group FY 2024 results | FY 2025 outlook Questions & Answers 3
Slide 4: Sales revenue on par with prior year; profitability remains robust
Sartorius Group Sales revenue on par with prior year; profitability remains robust Sartorius Group 2023 2024 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 3,396 3,381 -0.4 +0.1 Order intake 3,067 3,378 +10.1 +10.8 Underlying EBITDA2 963 945 -1.8 Underlying EBITDA2 margin i
Slide 5: Heterogeneous regional development influenced by general market conditions and product mix
Sartorius Group Heterogeneous regional development influenced by general market conditions and product mix EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +5.5% -6.1% +1.4% EMEA Americas 1,389 ~41% ~36% 1,316 1,280 1,200 799 792 €3,
Slide 6: Bioprocess Solutions: Positive demand momentum
Sartorius Group Bioprocess Solutions: Positive demand momentum Order intake Sales revenue Underlying EBITDA & margin € in millions € in millions € in millions +12.7% cc +0.9% cc +12.0% +0.5% +0.6% 2,693 2,678 2,690 900 782 787 55 2,404 800 50 55 700 400 600 45 50 500 300 45 40 400 40 200 29.2 29.3 3
Slide 7: Lab Products & Services: Resilient performance in challenging market
Sartorius Group Lab Products & Services: Resilient performance in challenging market Order intake Sales revenue Underlying EBITDA & margin € in millions € in millions € in millions -3.0% cc +4.1% cc -3.8% +3.3% -12.3% 663 684 718 691 180 158 25.1 22.9 2023 2024 2023 2024 2023 2024 ▪ Instruments busi
Slide 8: Strong cash flow; capex decreases as planned
Sartorius Group Strong cash flow; capex decreases as planned Sartorius Group 2023 2024 in % ▪ Extraordinary items driven by expenditures for in millions of € unless otherwise specified efficiency program and corporate projects Underlying EBITDA 963 945 -1.8 ▪ 2024 financial result impacted by higher
Slide 9: Deleveraging progresses as expected; committed to investment-grade rating
Sartorius Group Deleveraging progresses as expected; committed to investment-grade rating Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Group Dec. 3 1 , Dec. 31, in millions of € unless otherwise specified 2023 2024 6.0 5,000 5.0 Non-current assets 7,7891 7,989 4,000
Slide 10: Fundamental growth drivers intact and coming back into focus
Fundamental growth drivers intact and coming back into focus ~28,000 biologics in development; Pillars of growth CAGRs 2022–20273 increasingly innovative and diverse pipeline 1 Pharma market ~3-6% Lab equipment & consumables ~5% ~70% ~30% Biopharma market ~10% Other Advanced biologics therapies Bios
Slide 11: Deliberately cautious 2025 outlook: Profitable growth in both divisions
Sartorius Group Deliberately cautious 2025 outlook: Profitable growth in both divisions ▪ Life Science tools demand gradually picking up, but not yet expected at long-term average for FY 2025 ▪ Modest revenue growth above market targeted, driven by recurring business ▪ Ul EBITDA margin to slightly i
Slide 12: Agenda
Agenda Sartorius Group FY 2024 results | FY 2025 outlook Sartorius Stedim Biotech Group FY 2024 results | FY 2025 outlook Questions & Answers 12
Slide 13: Sales revenue on par with prior year; profitability remains robust
Sartorius Stedim Biotech Group Sales revenue on par with prior year; profitability remains robust Sartorius Stedim Biotech Group 2023 2024 in % in % cc1 in millions of € unless otherwise specified Sales revenue 2,775 2,780 +0.2 +0.6 Order intake 2,476 2,782 +12.3 +12.9 Underlying EBITDA2 785 779 -0.
Slide 14: Heterogeneous regional development influenced by general market conditions and product mix
Sartorius Stedim Biotech Group Heterogeneous regional development influenced by general market conditions and product mix EMEA Americas Asia|Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +5.9% -6.7% +4.0% EMEA Americas ~ 42% ~ 35% 1,159 1,054 628 639
Slide 15: Strong cash flow; capex decreases as planned
Sartorius Stedim Biotech Group Strong cash flow; capex decreases as planned Sartorius Stedim Biotech Group 2023 2024 in % in millions of € unless otherwise specified Underlying EBITDA 785 779 -0.8 ▪ Extraordinary items driven by expenditures for efficiency program and corporate projects Extraordinar
Slide 16: Deleveraging progresses as expected
Sartorius Stedim Biotech Group Deleveraging progresses as expected Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Stedim Biotech Dec. 31, Dec. 31, 4,000 6.0 Group 2023 2024 5.0 in millions of € unless otherwise specified 3,000 4.0 Non-current assets 6,3151 6,515 2,000
Slide 17: Deliberately cautious 2025 outlook: Profitable growth
Sartorius Stedim Biotech Group Deliberately cautious 2025 outlook: Profitable growth ▪ Life Science tools demand gradually picking up, but not yet expected at long-term average for FY 2025 ▪ Modest revenue growth above market targeted, driven by recurring business ▪ Ul EBITDA margin to slightly incr
Slide 18: Questions & Answers
18 Questions & Answers SARTORI
Slide 19: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha